A dietary supplement lists 50 mg of zinc per capsule. Another offers 200 micrograms of selenium. A third contains 10,000 IU of vitamin D3. On the label, these numbers impress. Inside the body, they can cause measurable damage.
The global supplement market operates on an implicit assumption: the higher the dose, the more effective the product. That assumption is wrong. Human biology does not respond linearly to micronutrient intake. It responds along a U-shaped curve.
The U-shaped curve: when benefit tips into toxicity
For the majority of essential micronutrients, the relationship between biological status and health outcomes follows a U-shape. Insufficient intake produces negative consequences. Excessive intake does too. Between the two lies an optimal window, often narrow, where benefit is maximal.
The relationship between micronutrient status and health follows a U-shaped curve for zinc, selenium, vitamin D, and iron. Excess is as harmful as insufficiency.
Margaret Rayman documented this with precision for selenium in a review published in The Lancet: individuals whose status is already adequate derive no benefit from additional supplementation, and may even experience adverse effects (PubMed). The determining factor is not the dose ingested, but the baseline status.
This principle applies to every bioactive in our formulas. And it governs our entire calibration process.
Zinc: when 50 mg per day destroys copper
Zinc is one of the most widely supplemented trace elements in the world. It is also one where excess produces the most insidious consequences.
The mechanism has been described since 1981, first in rat intestine (PubMed). Zinc and copper share the same intestinal absorption pathways. At doses exceeding 40 mg per day (less than what many commercially available supplements contain), zinc stimulates the production of metallothionein (a metal-binding storage protein) in enterocytes (the cells lining the intestinal wall). This metallothionein captures dietary copper, which is then eliminated during the natural turnover of the intestinal mucosa. The result: progressive copper depletion, silent for weeks or months (PubMed).
The consequences of this depletion are severe: sideroblastic anemia (a dysfunction in red blood cell production), neutropenia (a drop in white blood cells that weakens immunity), and in prolonged cases, irreversible damage to the spinal cord and peripheral nerves (PubMed). Willis et al. described three cases where the cause was only identified upon bone marrow examination, so poorly recognized is the link between zinc supplementation and copper depletion.
It is indefensible that an over-the-counter supplement can contain 50 mg of zinc without disclosing this risk.
Selenium: 200 micrograms, the threshold where everything shifts
Selenium may be the clearest illustration of U-shaped curve logic. Chiang et al. demonstrated, in a rigorous experimental model, a U-shaped relationship between selenium status and prostatic DNA damage: intermediate levels minimize lesions, while both low and high levels aggravate them (PubMed).
The SELECT clinical trial (Selenium and Vitamin E Cancer Prevention Trial) confirmed this logic at scale. In men whose selenium status was already adequate, supplementation at 200 micrograms per day provided no protection against prostate cancer. Worse: a trend toward increased risk of type 2 diabetes was observed in the selenium arm (PubMed).
The threshold for chronic toxicity (selenosis, meaning an excess of selenium in the body) manifests at modestly elevated blood concentrations: hair loss, brittle nails, gastrointestinal disturbances, fatigue. In 2008, a manufacturing error in a liquid supplement caused the largest selenosis outbreak in United States history, affecting 201 individuals (PubMed). The product contained 200 times the concentration stated on the label.
The tolerable upper intake level is set at 400 micrograms per day. Many supplements offer 200 micrograms, half that ceiling, without any knowledge of the user's baseline status. In an individual whose dietary intake is already sufficient, that additional dose crosses the optimal window.
Vitamin D3: the mirage of 10,000 IU
Vitamin D has become the subject of unprecedented popular enthusiasm. Doses of 5,000 to 10,000 IU per day circulate on forums and in non-clinical protocols. The pharmacological reality is more nuanced.
Marcinowska-Suchowierska et al. describe serum 25(OH)D concentrations above 150 ng/mL as typically encountered in vitamin D toxicity (PubMed). The picture includes hypercalcemia, hypercalciuria, nephrocalcinosis, polyuria, and dehydration; an isolated value does not establish that diagnosis. Well before this level, caution increases above 50 ng/mL, especially above 60.
A systematic review demonstrated that long-term vitamin D supplementation increases the risk of hypercalcemia and hypercalciuria (PubMed). This is precisely the problem with generic protocols: they ignore the individual variability of vitamin D metabolism, which depends on magnesium status, renal function, genetic factors, and sun exposure levels.
An individual with a serum 25(OH)D level of 30 ng/mL is not in the same category as one at 12 ng/mL. Giving both the same 10,000 IU dose ignores that measurement and far exceeds the tiers used by Singular.
Calibrate to the profile, not maximize the dose
Our approach rests on a principle that inverts the market's logic. The question is not "what is the maximum tolerable dose?" but "what is the optimal dose for this specific biological profile?"
Iron is another revealing example. Free iron in excess catalyzes free radical production via the Fenton reaction (a chemical reaction where iron generates aggressive oxidizing molecules). This is why iron supplementation is never systematic in our formulas: it is conditioned on a biological marker (ferritin) and an assessment of the inflammatory context (hs-CRP, a protein produced by the liver whose level rises during inflammation), because elevated ferritin in an inflammatory context does not indicate iron excess.
The mega-dose is an intellectual shortcut. It assumes that all organisms respond identically to the same quantity of the same bioactive. Fifty years of nutrition research demonstrate the opposite. Genetic polymorphisms (natural DNA variations between individuals), inflammatory status, microbiome composition, age, biological sex, nutrient-nutrient interactions: each variable can modify the response to a given intake. Zinc interferes with copper. Iron interferes with zinc. Magnesium participates in vitamin D metabolism, without the 25(OH)D value directly controlling its dose. Ignoring these interactions by stacking massive doses into a single capsule is not supplementation, but guesswork.
The U-shaped curve is itself a useful simplification of a broader phenomenon: hormesis. This concept describes the two-phase response of biological systems to a stress or an input. At low doses, the stimulus produces a beneficial effect: the body adapts and activates its repair mechanisms. Beyond a threshold, the same stimulus becomes harmful (PubMed). Each individual has their own hormetic window, defined by their genetics, metabolic state, and exposure history. A fixed dose cannot respect this variability.
There is a second problem that static protocols ignore: biological context evolves. Diet, activity, medications, and sun exposure can change results over time. For vitamin D, season helps interpret the sampling date but does not recalculate the dose. Singular offers reassessment around three months after starting or changing a formula, then roughly every six months for the whole formula; this service schedule is not a universal medical prescription.
The next step in supplementation is not about raising doses. It is about making them intelligible in light of each individual's biology, and adjusting them over time. That is an engineering problem, not a marketing one.
Frequently asked questions
References
- Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-68 (PubMed).
- Fischer PW, Giroux A, L'Abbé MR. The effect of dietary zinc on intestinal copper absorption. Am J Clin Nutr. 1981;34(9):1670-5 (PubMed).
- Fosmire GJ. Zinc toxicity. Am J Clin Nutr. 1990;51(2):225-7 (PubMed).
- Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123(1):125-31 (PubMed).
- Chiang EC, Shen S, Kengeri SS, et al. Defining the optimal selenium dose for prostate cancer risk reduction: insights from the U-shaped relationship between selenium status, DNA damage, and apoptosis. Dose Response. 2010;8(3):285-300 (PubMed).
- Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39-51 (PubMed).
- MacFarquhar JK, Broussard DL, Melstrom P, et al. Acute selenium toxicity associated with a dietary supplement. Arch Intern Med. 2010;170(3):256-61 (PubMed).
- Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, Płudowski P, Jones G. Vitamin D toxicity — a clinical perspective. Front Endocrinol. 2018;9:550 (PubMed).
- Malihi Z, Wu Z, Stewart AW, Lawes CM, Scragg R. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr. 2016;104(4):1039-51 (PubMed).
- Calabrese EJ, Baldwin LA. Defining hormesis. Hum Exp Toxicol. 2002;21(2):91-7 (PubMed).
